These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36920947)

  • 1. Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.
    Roche S; Gaule P; Winrow D; Mukherjee N; O'Neill F; Conlon NT; Meiller J; Collins DM; Canonici A; Fawsi MI; Estepa-Fernández A; Madden SF; Crown J; O'Donovan N; Eustace AJ
    PLoS One; 2023; 18(3):e0282512. PubMed ID: 36920947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
    Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
    Huber MC; Mall R; Braselmann H; Feuchtinger A; Molatore S; Lindner K; Walch A; Gross E; Schmitt M; Falkenberg N; Aubele M
    BMC Cancer; 2016 Aug; 16():615. PubMed ID: 27502396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
    Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
    Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
    Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
    PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.
    Yue CH; Liu JY; Chi CS; Hu CW; Tan KT; Huang FM; Pan YR; Lin KI; Lee CJ
    Anticancer Res; 2019 Aug; 39(8):4149-4164. PubMed ID: 31366500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
    Zhang H; Pelzer AM; Kiang DT; Yee D
    Cancer Res; 2007 Jan; 67(1):391-7. PubMed ID: 17210722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines.
    Gurdal H; Tuglu MM; Bostanabad SY; Dalkiliç B
    Int J Oncol; 2019 Apr; 54(4):1345-1356. PubMed ID: 30720056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.
    de Lint K; Poell JB; Soueidan H; Jastrzebski K; Vidal Rodriguez J; Lieftink C; Wessels LF; Beijersbergen RL
    Mol Cancer Ther; 2016 Jul; 15(7):1545-56. PubMed ID: 27196766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
    Litzenburger BC; Creighton CJ; Tsimelzon A; Chan BT; Hilsenbeck SG; Wang T; Carboni JM; Gottardis MM; Huang F; Chang JC; Lewis MT; Rimawi MF; Lee AV
    Clin Cancer Res; 2011 Apr; 17(8):2314-27. PubMed ID: 21177763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
    Chakraborty A; Hatzis C; DiGiovanna MP
    Breast Cancer Res Treat; 2017 May; 163(1):37-50. PubMed ID: 28236033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
    Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
    Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.
    Peterse EF; Cleven AH; De Jong Y; Briaire-de Bruijn I; Fletcher JA; Danen EH; Cleton-Jansen AM; Bovée JV
    BMC Cancer; 2016 Jul; 16():475. PubMed ID: 27418340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer.
    Xue L; Chen F; Yue F; Camacho L; Kothapalli S; Wei G; Huang S; Mo Q; Ma F; Li Y; Jiralerspong S
    Breast Cancer Res Treat; 2021 Jan; 185(1):73-84. PubMed ID: 32940848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
    Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
    Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
    Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Resistance Mechanism to IGF-IR Targeting in Human Triple Negative MDA-MB-231 Breast Cancer Cells.
    Tsui J; Qi S; Perrino S; Leibovitch M; Brodt P
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33916323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
    Wu W; Ma J; Shao N; Shi Y; Liu R; Li W; Lin Y; Wang S
    PLoS One; 2017; 12(1):e0169229. PubMed ID: 28046018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.
    Ahearn TU; Peisch S; Pettersson A; Ebot EM; Zhou CK; Graff RE; Sinnott JA; Fazli L; Judson GL; Bismar TA; Rider JR; Gerke T; Chan JM; Fiorentino M; Flavin R; Sesso HD; Finn S; Giovannucci EL; Gleave M; Loda M; Li Z; Pollak M; Mucci LA;
    Carcinogenesis; 2018 Dec; 39(12):1431-1437. PubMed ID: 30165429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.